SOUTH PLAINFIELD, N.J. (AP) _ PTC Therapeutics Inc. (PTCT) on Thursday reported a loss of $133.6 million in its third quarter.

The South Plainfield, New Jersey-based company said it had a loss of $1.89 per share.

The results did not meet Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of $1.78 per share.

The biopharmaceutical company posted revenue of $138.7 million in the period, which topped Street forecasts. Three analysts surveyed by Zacks expected $119.4 million.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on PTCT at https://www.zacks.com/ap/PTCT

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News